In this interview, Sanyogitta Puri, Associate Director (AstraZeneca, Cambridge, UK), explores AstraZeneca’s involvement in the gene and cell therapy field. Puri describes AstraZeneca’s goals to tap into the potential of these promising modalities, bringing patients the benefits of new therapies. Puri also explains the key challenges encountered when working with gene and cell therapy products from a manufacturing and CMC perspective.
Q How is AstraZeneca involved in gene and cell therapies?
Q What are the challenges with working with gene and cell therapy products?
Q Where do you hope this field will be in 5–10 years’ time?